Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Change in Account Payables (2022 - 2024)

Adial Pharmaceuticals' Change in Account Payables history spans 3 years, with the latest figure at -$262735.0 for Q4 2024.

  • For Q4 2024, Change in Account Payables fell 255.41% year-over-year to -$262735.0; the TTM value through Dec 2024 reached -$47942.0, down 299.24%, while the annual FY2024 figure was -$47942.0, 299.24% down from the prior year.
  • Change in Account Payables for Q4 2024 was -$262735.0 at Adial Pharmaceuticals, down from $1392.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $169062.0 in Q4 2023 and bottomed at -$262735.0 in Q4 2024.
  • The 3-year median for Change in Account Payables is $19989.0 (2022), against an average of -$671.17.
  • The largest annual shift saw Change in Account Payables surged 15597.49% in 2023 before it tumbled 255.41% in 2024.
  • A 3-year view of Change in Account Payables shows it stood at $1077.0 in 2022, then soared by 15597.49% to $169062.0 in 2023, then crashed by 255.41% to -$262735.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Change in Account Payables are -$262735.0 (Q4 2024), $1392.0 (Q3 2024), and $139258.0 (Q2 2024).